Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer

By Zhaohui Huang, Dan Huang, S. Ni, Zhilei Peng, W. Sheng, Xiang Du. International Journal of Cancer, 2010

990 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “…neoplasias was shown to reﬂect the pattern observed in the tumour tissues, suggesting the attractive possibility of using circulating miRNAs as easily detectable tumour biomarkers (Lawrie et al, 2008), especially for early diagnosis (Heneghan et al, 2010; Huang et al, 2010; Xing et al, 2010).”
Circulating Exosomal microRNAs as Biomarkers of Colon Cancer (2014, background): “Several reports have suggested the use of circulating miRNAs in whole plasma or serum, including miR-141, miR-21, miR-221, miR-29, and miR92a, as diagnostic biomarkers of CRC [26–30].”
microRNA as Biomarkers and Diagnostics (2016, background): “…a tumor suppressor in lung cancer (Fabbri et al., 2007), hepatocellular carcinoma (Xiong et al., 2010)], and leukemia (Pekarsky and Croce, 2010) but is significantly elevated in the plasma of patients with advanced colorectal neoplasia (Huang et al., 2010) and ovarian cancer (Resnick et al., 2009).”
MicroRNAs in body fluids—the mix of hormones and biomarkers (2011, positive): “Interestingly, another study also found that the levels of miR-92a (and of miR-29a ) were significantly higher in plasma samples from patients with advanced-stage colorectal cancer than in those from healthy controls”